MX342697B - Proceso para produccion de sales de metanosulfonato de ralfinamida o sus enantiomeros r. - Google Patents
Proceso para produccion de sales de metanosulfonato de ralfinamida o sus enantiomeros r.Info
- Publication number
- MX342697B MX342697B MX2012012093A MX2012012093A MX342697B MX 342697 B MX342697 B MX 342697B MX 2012012093 A MX2012012093 A MX 2012012093A MX 2012012093 A MX2012012093 A MX 2012012093A MX 342697 B MX342697 B MX 342697B
- Authority
- MX
- Mexico
- Prior art keywords
- water
- salt
- acetone
- carbon atoms
- production
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- -1 ralfinamide methanesulfonate salts Chemical class 0.000 title abstract 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 abstract 3
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- 231100000024 genotoxic Toxicity 0.000 abstract 2
- 230000001738 genotoxic effect Effects 0.000 abstract 2
- 239000012535 impurity Substances 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 239000013557 residual solvent Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10161207 | 2010-04-27 | ||
| PCT/EP2011/055309 WO2011134763A1 (en) | 2010-04-27 | 2011-04-06 | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012012093A MX2012012093A (es) | 2012-12-17 |
| MX342697B true MX342697B (es) | 2016-10-10 |
Family
ID=42634917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012012093A MX342697B (es) | 2010-04-27 | 2011-04-06 | Proceso para produccion de sales de metanosulfonato de ralfinamida o sus enantiomeros r. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9505708B2 (enExample) |
| EP (1) | EP2563355B1 (enExample) |
| JP (3) | JP5808392B2 (enExample) |
| KR (1) | KR101851118B1 (enExample) |
| CN (2) | CN105037188B (enExample) |
| AR (1) | AR085171A1 (enExample) |
| AU (1) | AU2011246707B2 (enExample) |
| BR (1) | BR112012027623B1 (enExample) |
| CA (1) | CA2794389C (enExample) |
| CY (1) | CY1117879T1 (enExample) |
| DK (1) | DK2563355T3 (enExample) |
| EA (1) | EA021389B1 (enExample) |
| ES (1) | ES2590128T3 (enExample) |
| HR (1) | HRP20161077T1 (enExample) |
| HU (1) | HUE030504T2 (enExample) |
| IL (1) | IL222532A (enExample) |
| LT (1) | LT2563355T (enExample) |
| ME (1) | ME02509B (enExample) |
| MX (1) | MX342697B (enExample) |
| NZ (2) | NZ602648A (enExample) |
| PL (1) | PL2563355T3 (enExample) |
| PT (1) | PT2563355T (enExample) |
| RS (1) | RS55084B1 (enExample) |
| SI (1) | SI2563355T1 (enExample) |
| SM (1) | SMT201600266B (enExample) |
| TW (1) | TWI492919B (enExample) |
| WO (1) | WO2011134763A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2563355T3 (pl) * | 2010-04-27 | 2016-12-30 | Sposób wytwarzania soli stanowiących metanosulfoniany ralfinamidu lub jego enancjomerów R | |
| CN103804341B (zh) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 酰胺衍生物及其医药用途 |
| CN104761531B (zh) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 镇痛活性化合物及其医药用途 |
| CN104292128A (zh) * | 2014-07-01 | 2015-01-21 | 南京正科制药有限公司 | 一种沙芬酰胺晶型a |
| CN115368310B (zh) * | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| DE60209152T2 (de) | 2001-09-03 | 2006-08-03 | Newron Pharmaceuticals S.P.A. | Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid |
| EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| JP2006515326A (ja) * | 2003-01-30 | 2006-05-25 | ダイノジェン ファーマシューティカルズ， インコーポレイテッド | 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用 |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2005018627A1 (en) | 2003-08-25 | 2005-03-03 | Newron Pharmaceuticals, Spa | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| RU2391973C2 (ru) * | 2004-09-10 | 2010-06-20 | Ньюрон Фармасьютикалс С.П.А. | Применение (галобензилокси)бензиламино-пропанамидов для производства лекарственных средств, действующих как селективные модуляторы натриевых и/или кальциевых каналов |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| RS55464B1 (sr) * | 2006-06-19 | 2017-04-28 | Newron Pharm Spa | 2-[4-(3- i 2 fluorbenziloksi) benzilamino] propanamidi visokog stepena čistoće za upotrebu kao lekovi i farmaceutski preparati koji ih sadrže |
| JP5315674B2 (ja) * | 2007-11-19 | 2013-10-16 | セントラル硝子株式会社 | 非水電池用電解液及びこれを用いた非水電池 |
| JP5460613B2 (ja) * | 2007-12-11 | 2014-04-02 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 高純度を有する２−［４−（３−または２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法 |
| KR101500962B1 (ko) | 2007-12-19 | 2015-03-10 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 정신 장애의 치료에 유용한 알파아미노아미드 유도체 |
| WO2009109334A1 (en) | 2008-03-07 | 2009-09-11 | Newron Pharmaceuticals S.P.A. | (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| PL2563355T3 (pl) * | 2010-04-27 | 2016-12-30 | Sposób wytwarzania soli stanowiących metanosulfoniany ralfinamidu lub jego enancjomerów R |
-
2011
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active Active
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en not_active Ceased
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
-
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
-
2016
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
-
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| EP2653475A4 (en) | PROCESS FOR PREPARING A WATER-FREE CRYSTAL-CONTAINING POWDER OF 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID | |
| MX342697B (es) | Proceso para produccion de sales de metanosulfonato de ralfinamida o sus enantiomeros r. | |
| EP2290092A4 (en) | PROCESS FOR THE PREPARATION OF L-AMINO ACID | |
| EP2395096A4 (en) | PROCESS FOR THE PREPARATION OF L-AMINO ACID | |
| CL2008000099A1 (es) | Compuestos derivados de serinamidas sustituidas por heteroaroilo; proceso para preparar dichos compuestos; compuesto derivado de heteroaroilo; composicion; proceso de preparacion de dicha composicion; metodo para controlar la vegetacion no deseada; y | |
| IN2014MN01839A (enExample) | ||
| MX2013011257A (es) | Proceso para la preparacion de dronedarona por n-butilacion. | |
| IN2014CN03482A (enExample) | ||
| EP2471943A4 (en) | PROCESS FOR THE PREPARATION OF L-AMINO ACID | |
| EP2093210A4 (en) | PROCESS FOR THE PREPARATION OF TEREPHTHALIC ACID | |
| EP2447243A4 (en) | PROCESS FOR THE PREPARATION OF KETOMALONIC COMPOUNDS OR HYDRATES THEREOF | |
| CL2011000296A1 (es) | Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados. | |
| EP2519510A4 (en) | PROCESS FOR PRODUCING HIGH-PURITY, WATER-FREE AND CRYSTALLINE DOCETAXEL | |
| EP2599769A4 (en) | PROCESS FOR PREPARING A CARBOXYLIC ACID AMID | |
| EP2471942A4 (en) | PROCESS FOR THE PREPARATION OF L-AMINO ACID | |
| IL217509A0 (en) | Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid by poor-solvent addition method | |
| WO2013172741A3 (ru) | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси) циклогексен-1-карбоновые кислоты, их эфиры и способ применения | |
| EP3305754A4 (en) | METHOD FOR PRODUCING HIGHLY UNSATURATED FATTY ACID WITH A HIGH PURITY OF HIGH HIGH PURITY | |
| ITMI20120311A1 (it) | Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato | |
| EP2298756A4 (en) | PROCESS FOR THE PREPARATION OF 3-METHYL-2-THIOPHENIC CARBONIC ACID | |
| EP2784063A4 (en) | PROCESS FOR THE PREPARATION OF BETA-MERCAPTOCARBONIC ACID | |
| EP2770062A4 (en) | PREPARATION FOR ORGANIC ACID BY COA TRANSFERASE | |
| EP2351734A4 (en) | PREPARATION OF SULFURIC ACID SALT | |
| EP2397545A4 (en) | PROCESS FOR PREPARING AN AMINO ACID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |